» Articles » PMID: 35008607

Colonic Mucosal Immune Activation in Mice with Ovalbumin-Induced Allergic Airway Disease: Association Between Allergic Airway Disease and Irritable Bowel Syndrome

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Jan 11
PMID 35008607
Authors
Affiliations
Soon will be listed here.
Abstract

Recent studies on the pathophysiology of irritable bowel syndrome (IBS) have focused on the role of mast cells (MCs) in intestinal mucosal immunity. A link between allergic airway diseases (AADs) and IBS has been suggested because both diseases have similar pathophysiology. We aimed to investigate whether the induction of AAD in mice could lead to inflammation of the colonic mucosa, similar to IBS. We also evaluated whether this inflammatory response could be suppressed by administering a therapeutic agent. Mice were divided into three groups: control, AAD-induced, and salbutamol-treated. An AAD mouse model was established by intraperitoneal injection and nasal challenge with ovalbumin. Mice with AAD were intranasally administered salbutamol. Analyses of cytokine levels, MC count, and tryptase levels in the intestinal mucosa were performed to compare the changes in inflammatory responses among the three groups. Inflammation was observed in the intestinal mucosa of mice in the AAD group. This inflammation in AAD mice was suppressed after salbutamol treatment. Our study demonstrates that AAD induces an inflammatory response similar to that in IBS, suggesting a possible association between IBS and AADs. In patients with IBS with such allergic components, salbutamol may have the potential to alleviate the inflammatory response.

Citing Articles

Metabotropic glutamate receptor-8 relieves neonatal maternal separation-induced visceral hypersensitivity in rats by regulating expression of TNF-α.

Wang X, Shao L, Hua H, Chen Y Ann Transl Med. 2023; 11(2):118.

PMID: 36819583 PMC: 9929757. DOI: 10.21037/atm-22-6452.


Sirtuin 7 Inhibitor Attenuates Colonic Mucosal Immune Activation in Mice-Potential Therapeutic Target in Inflammatory Bowel Disease.

Kim S, Byun J, Jung S, Kim B, Lee K, Jeon H Biomedicines. 2022; 10(11).

PMID: 36359214 PMC: 9687268. DOI: 10.3390/biomedicines10112693.

References
1.
Tobin M, Moparty B, Farhadi A, DeMeo M, Bansal P, Keshavarzian A . Atopic irritable bowel syndrome: a novel subgroup of irritable bowel syndrome with allergic manifestations. Ann Allergy Asthma Immunol. 2008; 100(1):49-53. DOI: 10.1016/S1081-1206(10)60404-8. View

2.
Holtmann G, Ford A, Talley N . Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2017; 1(2):133-146. DOI: 10.1016/S2468-1253(16)30023-1. View

3.
Vivinus-Nebot M, Dainese R, Anty R, Saint-Paul M, Nano J, Gonthier N . Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells. Am J Gastroenterol. 2011; 107(1):75-81. DOI: 10.1038/ajg.2011.315. View

4.
Serna H, Porras M, Vergara P . Mast cell stabilizer ketotifen [4-(1-methyl-4-piperidylidene)-4h-benzo[4,5]cyclohepta[1,2-b]thiophen-10(9H)-one fumarate] prevents mucosal mast cell hyperplasia and intestinal dysmotility in experimental Trichinella spiralis inflammation in the rat. J Pharmacol Exp Ther. 2006; 319(3):1104-11. DOI: 10.1124/jpet.106.104620. View

5.
Rayapudi M, Mavi P, Zhu X, Pandey A, Abonia J, Rothenberg M . Indoor insect allergens are potent inducers of experimental eosinophilic esophagitis in mice. J Leukoc Biol. 2010; 88(2):337-46. PMC: 2908938. DOI: 10.1189/jlb.0110025. View